United Therapeutics CEO Martine Rothblatt Exercises Options and Sells $5.58 Million of Stock
Chairperson and CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares for $5.58 million on Monday, according to a Form 4 filed Tuesday.
Rothblatt paid the $117.76 exercise price on the options and sold the shares in multiple trades at an average of $587.74 per share. The shares were held in a family trust.
The plan behind it
The exercise and sale were made under a pre-arranged Rule 10b5-1 trading plan Rothblatt adopted on Nov. 7, 2025, the filing says.
That plan continues until the earlier of two events: the exercise of 1,734,410 stock options, all of which expire on March 15, 2027, or Dec. 31, 2026. The options vested in equal one-third installments in March 2021, 2022 and 2023, according to the filing.
After the sale, the trust that made it held 324,443 shares. Rothblatt reports other United Therapeutics holdings through additional family trusts.
By the numbers
- Options exercised: 9,500 at $117.76
- Shares sold: 9,500
- Proceeds: $5,583,501
- Average sale price: $587.74
- Options covered by the plan: 1,734,410, expiring March 15, 2027
Sources
- Form 4, United Therapeutics Corporation, Martine A. Rothblatt, filed Nov. 17, 2026, accession 0001106578-26-000190
This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.
Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence. SI may make mistakes.